Dr. Putman has more than 25 years of scientific and management experience in large and small pharmaceutical companies, including Syntex, Roche, UCB and Kadmus. Dr. Putman co-founded Anvyl LLC, a biotech that is developing cutting-edge therapies to address disorders of the central nervous system (CNS). Anvyl was founded with the goal of providing safe and efficacious therapies currently desperately needed for treating CNS conditions, like cognitive-deficit disorders, anxiety and pain. Using its expertise in allosteric modulation, Anvyl is creating a broad pipeline of first-in-class drugs to fill unmet medical conditions including Alzheimer’s disease, schizophrenia, autism spectrum disorder, traumatic brain injury and other CNS disorders such as epilepsy, anxiety and pain. Dr. Putman has a BS in Chemical Engineering, a Ph.D. in Organic Chemistry and was a postdoctoral fellow at Cornell University.
Current role